In summary, our data suggested that suppression of NF-κB activation or expression mediated by chemical inhibitor PDTC could significantly improve liver function and reduce mortality of FHF mouse model, and NF-κB would be a potential new therapeutic target for FHF. Here, NFKB1 is linked to TNF receptor 1-associated periodic fever syndrome.